Targeted cisplatin infusion for diffuse midline glioma in young patients
Part of Brain & nervous system, Cancer clinical trials.
This trial is testing a new way to give the chemotherapy drug cisplatin directly to the tumor using tiny particles. It is for children and young adults who have a specific type of brain tumor called diffuse midline glioma (including DIPG) that has already been treated with radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient must be between 3 and 21 years old.
- They must have a type of brain tumor called diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG).
- They must have completed radiation therapy within the last 4 to 12 weeks, and it must have started within 6 weeks of diagnosis.
- They need to have had an MRI 4 to 6 weeks after radiation to confirm they are eligible.
- They must have a good performance status (able to carry on with daily activities) and no major medical problems like heart issues or infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial compares two types of radiation therapy for children with diffuse intrinsic pontine glioma (DIPG), a rare brain tumor. It aims to see which treatment may be more effective while helping you understand your options.
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Hear when a new Diffuse Midline Glioma (DMG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.